Results 111 to 120 of about 47,525 (299)

Clinical applications of pharmacogenomics [PDF]

, 2017
Indexación: Scopus.Pharmacogenomics is an emergent field aimed at tailoring pharmacological therapy. Genetic polymorphisms can modify the expression and function of enzymes and proteins involved in drug metabolism, affecting absorption, distribution ...
Cayún, J.P., Escalante, P., Gallegos, B., Lares-Asseff, I., Meneses, F., Miranda, C., Quiñones, L., Roco, Á., Varela, N., Zaruma-Torres, F.   +9 more
core   +1 more source

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, EarlyView.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

Genetic polymorphism of cytochrome p450 (2C19) enzyme in Iranian Turkman ethnic group [PDF]

, 2013
Objective: Different findings indicate that CYP2C plays a clinical role in determining interindividual and interethnic differences in drug effectiveness. The ethnic differences in the frequency of CYP2C19 mutant alleles continue to be a significant study
Ataby, O.A., Mansourian, A.R., Marjani, A., Samai, N.M., Tabari, R.G.   +4 more
core   +2 more sources

Recent Utilization of Pediatric Extrapolation and Modeling and Simulation Approaches in Pediatric Drug Development in Japan

The Journal of Clinical Pharmacology, EarlyView.
Abstract In Japan, the percentage of approved drugs with pediatric indications increased to 30% in 2010‐2015, but no further increase was observed through 2020. The Ministry of Health, Labor, and Welfare in Japan presented draft future directions to promote pediatric drug development, where the modeling and simulation (M&S) approach was introduced as a
Akinori Nakashima, Akihide Tsujimoto, Masako Saito, Jun Takeda, Makiko Natori, Satoshi Shoji   +5 more
wiley   +1 more source

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [PDF]

, 2017
Background Adjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect
Biasi, Maria Olivia, Bouzyk, Mark, Coates, Alan S., Debled, Marc, Dell'Orto, Patrizia, Ditzel, Henrik J., Gelber, Richard D., Goldhirsch, Aron, Kammler, Roswitha, Leyland-Jones, Brian, Lyng, Maria B., Maibach, Rudolf, Neven, Patrick, Pagani, Olivia, Price, Karen N., Rae, James M., Regan, Meredith M., Tang, Weining, Thürlimann, Beat, Viale, Giuseppe   +19 more
core  

Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

, 2015
Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 ...
A Ahmad, A Gaedigk, A Tfayli, B Chowbay, B Eccles, B Ganchev, B Makubate, C Davies, C McCowan, D Eccles, D Eccles, DL Hershman, DL Hershman, E Copson, E Schaeffeler, Early Breast Cancer Trialists’ Collaborative Group, EJA Bowles, EP Winer, H Brauch, H Brauch, H Brauch, H Brauch, I Zineh, J S L Lim, J Sistonen, JE Abraham, JK Coller, JM Rae, JM Rae, JSL Lim, K Dickschen, K Kiyotani, K Kiyotani, K Kiyotani, KJ Ruddy, L Madlensky, M Dowsett, M Eichelbaum, M Gnant, M Schwab, M Z Habbal, MA Province, MD Johnson, MF Barginear, MJ Ratain, MM Regan, MM Regan, MP Goetz, N K Zgheib, N S Wong, O Pagani, P Saladores, PH Saladores, PM Ravdin, PY Maximov, R C H Ng, R Dent, R McCague, Richard G. Gray, RR Love, RT Chlebowski, S Gerty, S Winter, T Mürdter, TE Mürdter, TL Lash, UM Zanger, UM Zanger, VC Jordan, VO Dezentjé, W Lorizio, W Schroth, W Schroth, W Schroth, WJ Irvin Jr, WJ Lu, Y Jin, Y S Yap, YC Lim, Z Awada, Z Desta   +80 more
core   +1 more source

Population Pharmacokinetic and Exposure‐Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management

The Journal of Clinical Pharmacology, EarlyView.
Abstract Valbenazine improved chorea in individuals with Huntington's disease compared to placebo in a phase 3, placebo‐controlled study (KINECT‐HD). Population pharmacokinetics (PK) and exposure–response (E–R) analyses focused on understanding the PK characteristics of valbenazine and its active metabolite, [+]‐α‐dihydrotetrabenazine ([+]‐α‐HTBZ), and
Hoa Q. Nguyen, Ryan L. Crass, Sunny Chapel, Han‐Yi Steve Kuan, Gordon Loewen, Satjit Brar   +5 more
wiley   +1 more source

From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment

The Journal of Clinical Pharmacology, EarlyView.
Abstract Endoxifen is the most active metabolite of tamoxifen and plays a central role in its therapeutic efficacy. However, significant interindividual variability in endoxifen plasma concentrations, driven by both genetic and non‐genetic factors, may result in subtherapeutic exposure for a substantial subset of patients.
Ana Flávia Mendes Batista, Letícia Penteado Petrolli, Maria Paula Marques Pereira, Adriana Rocha, Jurandyr Moreira de Andrade, Vera Lucia Lanchote, João Paulo Bianchi Ximenez   +6 more
wiley   +1 more source

Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical Studies

The Journal of Clinical Pharmacology, EarlyView.
Abstract Miricorilant is a novel selective glucocorticoid receptor (GR) modulator with mixed agonist/antagonist effects at the GR and modest antagonism at the mineralocorticoid receptor that is being developed for the treatment of metabolic dysfunction‐associated steatohepatitis.
Hazel J. Hunt, Kirsteen M. Donaldson, Jeevan R. Kunta, Joseph M. Custodio   +3 more
wiley   +1 more source

Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. [PDF]

, 1993
William E. Evans, Mary V. Relling, Atiqur Rahman, H. L. McLeod, Edward P. Scott, Jin Lin   +5 more
openalex   +1 more source